Marchiafava Bignami disease (or beta-thalassemia) is a hereditary disorder characterized by a disorder in the synthesis of beta chains of hemoglobin. This leads to a lack of normal hemoglobin in the blood, which in turn causes anemia. The disease has an autosomal recessive type of inheritance and in most cases manifests itself in early childhood. The main symptoms include severe anemia, changes in the skeletal system, enlargement of the spleen and liver, and hormonal disorders. The pathogenesis of this disease is associated with mutations in the HBB gene, which leads to a change in the structure of hemoglobin, and, as a consequence, to its functional disorders.
History of the disease and interesting historical facts
The first clinical description of Marchiafava Bignami disease dates back to 1925, when Italian researchers Fernando Marchiafava and Gaetano Bignami described a group of patients with severe anemia and severe changes in the skull bones. Similar cases were observed in Mediterranean areas, which led to the initial hypothesis of a connection between the disease and a genetic predisposition of the inhabitants of these regions. It was later established that the disease is common not only in the Mediterranean, but also in various ethnic groups, including Indian and African populations. By the mid-20th century, scientists began to study the genetic basis of the disease, which led to the discovery of the role of mutations in the HBB gene.
Epidemiology
According to the World Health Organization, Marchiafava Bignami disease is one of the most common inherited diseases. There are approximately 1.5% cases of beta thalassemia in the population worldwide, equivalent to 300,000 new cases annually. The incidence rate is particularly high in Mediterranean countries, the Middle East, South Asia and Southeast Asia. In some regions, such as Cyprus and Greece, the carrier frequency can reach 15-20%, indicating a significant prevalence of the disease in these populations.
Genetic predisposition to this disease
Marchiafava Bignami disease is caused by mutations in the HBB gene, which is located on chromosome 11. There are over 200 known mutations that can cause the disease. The most common mutations are nucleotide substitutions, deletions, and insertions that disrupt the normal synthesis of hemoglobin beta chains. These mutations can be either spontaneous or inherited, passed from parents to children. Research shows that having one or two alleles of the mutant gene significantly increases the risk of developing the disease and its severity.
Risk factors for the development of this disease
Risk factors for the development of Marchiafava Bignami disease include both genetic and environmental factors. The main risk factors include:
- Heredity: Having affected relatives increases the likelihood of developing the disease.
- Ethnicity: There is an increased risk in people of certain ethnic groups, such as Greeks, Italians, and Indians.
- Geographic factors: regions with high incidence rates, such as the Mediterranean.
- Changes in living conditions: Environmental factors such as pollution can aggravate the course of the disease.
Diagnosis of this disease
Diagnosis of Marchiafava Bignami disease requires a comprehensive approach, including clinical, laboratory and radiological methods. The main symptoms of the disease depend on its severity and may include:
- Fatigue and weakness.
- Enlargement of the spleen and liver.
- Changes in bone structure, including skull deformities.
- Hormonal disorders.
The following studies are used to confirm the diagnosis:
- General blood test for hemoglobin level and presence of reticulocytes.
- Hemoglobin electrophoresis for the determination of cases of beta-thalassemia.
- Molecular genetic studies to identify mutations in the HBB gene.
- Radiological studies to assess changes in the skeletal system.
Differential diagnosis includes exclusion of other forms of anemia, such as iron deficiency anemia and anemia syndromes caused by vitamin and mineral deficiencies.
Treatment
Treatment of Marchiafava Bignami disease requires a multidisciplinary approach based on the severity of the disease, the patient's age, and the presence of comorbid conditions. The main areas of treatment include:
- General treatment: prescription of a diet with increased iron and vitamin content, as well as supportive therapy.
- Pharmacological treatment: use of drugs such as iron chelators to reduce excess iron accumulation in the body.
- Surgical treatment: In some cases, a bone marrow or stem cell transplant may be required.
- Other treatments: Gene therapies are in clinical trials and may be an important direction in the future.
List of medications used to treat this disease
Medications used to treat Marchiafava Bignami disease may include:
- Desferal (deferoxamine) is an iron chelator.
- Ferracov (deferiprone) is an alternative drug for removing excess iron.
- Olanzapine – in some cases to maintain the mental state of patients.
- Folic acid – to improve the general condition of the blood.
Disease monitoring
Monitoring the disease involves regular observation of the patient's condition, monitoring of hemoglobin and iron levels, and monitoring for possible complications. The prognosis depends on the severity of the disease and can range from relatively mild to severe, requiring ongoing treatment. Possible complications include heart failure, infectious diseases that occur against the background of anemia, and problems with the endocrine system.
Age-related features of the disease
Marchiafava Bignami disease can manifest at different ages. In children, symptoms usually appear at an early age, while adults may have a milder course of the disease. Newborns often have a more severe form that requires immediate treatment. In the elderly, the course of the disease may be blurred, and diagnosis may be difficult due to concomitant diseases.
Questions and Answers
- What is the genetic heritage of Marchiafava Bignami disease? The disease is transmitted in an autosomal recessive manner, and both parents must be carriers of the gene for a child to inherit the disease.
- What symptoms may indicate the disease? The main symptoms include anemia, enlargement of the spleen and liver, as well as bone deformities and changes in hormonal levels.
- How are diagnostic procedures performed? Diagnostics includes a complete blood count, hemoglobin electrophoresis, molecular genetic studies and radiological methods.
- What medications are used to treat the disease? Iron chelators such as Desferal and Ferracov are used, as well as vitamins to maintain the patient's general condition.
- What is the life expectancy of patients with this disease? Life expectancy depends on the severity of the disease and the quality of treatment; thanks to modern methods of supportive therapy, many patients can live a full life.
